This advert is not available!
Lund University was founded in 1666 and is repeatedly ranked among the world’s top universities. The University has around 47 000 students and more than 8 800 staff based in Lund, Helsingborg and Malmö. We are united in our efforts to understand, explain and improve our world and the human condition.
Lund University welcomes applicants with diverse backgrounds and experiences. We regard gender equality and diversity as a strength and an asset.
Description of the workplace and research group
The position is based at the Department of Clinical Sciences in Malmö, in the Diabetic Complication unit, which is headed by Professor Maria Gomez and is part of the Lund University Diabetes Centre (LUDC; www.ludc.med.lu.se).
Today, 537 million adults (20–79 years) are living with diabetes, i.e., 1 in 10, and this number is predicted to rise to 643 million by 2030 and 783 million by 2045. This will inevitably result in increased number of patients suffering from DKD and cardiovascular complication such as heart failure (HF).
An overarching aim of our research is to identify and validate new prognostic and predictive biomarkers that can help us identify which patients will experience a more rapid aggressive disease progression, and which patients are more likely to respond or not to a specific treatment.
Work duties and areas or responsibilities
The research will be carried out within the framework of a joint collaboration between Lund University and Novo Nordisk entitled “Type 2 diabetes (T2D) patient segmentation focusing on fast progressors to T2D-complications”. The candidate will also be involved in the ongoing iBEAt study, initiated with support from EU project BEAt-DKD (https://www.beat-dkd.eu/), in IMI project SOPHIA (https://imisophia.eu/) and in the HORIZON project PRIME-CKD (https://umcgresearch.org/w/umcg-lead-collaborations-to-advance-precision-medicine-in-chronic-kidney-disease).The aim of this project is to leverage longitudinal omics data and advanced data analytics to sub-phenotype people living with T2D and elucidate the role of insulin resistance in driving the development of CKD and HF, identifying molecular signatures underlying this link, generating actionable insights and potential therapeutic targets for early intervention.
Qualifications
Requirements for the position are:
Meritorious for the position are:
Terms of employment
This is a full-time employment limited to 3 years. Preliminary start date 2024-04-01 or according to agreement. The period of employment is determined in accordance with the agreement “Avtal om tidsbegränsad anställning som postdoktor” (“Agreement on fixed-term employment as a post-doctoral researcher”) between SACO-S, OFR/S and SEKO, dated February 1, 2022
Type of employment | Temporary position |
---|---|
Contract type | Full time |
First day of employment | 2024-04-01 eller enligt överenskommelse |
Number of positions | 1 |
Full-time equivalent | 100 |
City | Malmö |
County | Skåne län |
Country | Sweden |
Reference number | PA2024/593 |
Contact |
|
Union representative |
|
Published | 04.Mar.2024 |
Last application date | 25.Mar.2024 11:59 PM CET |